BridgeBio Pharma, Inc. to Post Q1 2023 Earnings of ($0.92) Per Share, SVB Leerink Forecasts (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIOGet Rating) – Equities researchers at SVB Leerink issued their Q1 2023 earnings estimates for BridgeBio Pharma in a report issued on Monday, January 23rd. SVB Leerink analyst M. Foroohar forecasts that the company will earn ($0.92) per share for the quarter. SVB Leerink currently has a “Outperform” rating and a $19.00 target price on the stock. The consensus estimate for BridgeBio Pharma’s current full-year earnings is ($3.89) per share. SVB Leerink also issued estimates for BridgeBio Pharma’s FY2024 earnings at ($2.19) EPS.

BridgeBio Pharma (NASDAQ:BBIOGet Rating) last posted its quarterly earnings data on Thursday, November 3rd. The company reported ($0.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.09. The company had revenue of $0.34 million during the quarter, compared to analyst estimates of $6.26 million.

Separately, JPMorgan Chase & Co. decreased their price objective on BridgeBio Pharma from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, November 18th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.80.

BridgeBio Pharma Stock Up 11.4 %

NASDAQ BBIO opened at $9.49 on Tuesday. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -2.82 and a beta of 0.62. BridgeBio Pharma has a twelve month low of $4.98 and a twelve month high of $12.64. The stock has a fifty day simple moving average of $8.52 and a 200 day simple moving average of $9.73.

Insiders Place Their Bets

In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 19,678 shares of the stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $9.40, for a total transaction of $184,973.20. Following the completion of the sale, the chief financial officer now directly owns 341,264 shares in the company, valued at approximately $3,207,881.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other BridgeBio Pharma news, CFO Brian C. Stephenson sold 19,678 shares of the stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $9.40, for a total transaction of $184,973.20. Following the completion of the sale, the chief financial officer now directly owns 341,264 shares in the company, valued at approximately $3,207,881.60. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Brian C. Stephenson sold 61,040 shares of the stock in a transaction dated Thursday, January 5th. The stock was sold at an average price of $7.67, for a total value of $468,176.80. Following the sale, the chief financial officer now owns 280,224 shares of the company’s stock, valued at $2,149,318.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 235,358 shares of company stock worth $1,899,166. Company insiders own 29.60% of the company’s stock.

Institutional Trading of BridgeBio Pharma

Large investors have recently made changes to their positions in the company. Itau Unibanco Holding S.A. acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $28,000. Quantbot Technologies LP grew its stake in shares of BridgeBio Pharma by 500.0% in the 1st quarter. Quantbot Technologies LP now owns 4,200 shares of the company’s stock valued at $42,000 after buying an additional 3,500 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of BridgeBio Pharma by 1,501.5% in the 3rd quarter. Daiwa Securities Group Inc. now owns 8,808 shares of the company’s stock valued at $88,000 after buying an additional 8,258 shares during the period. Dupont Capital Management Corp acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter valued at about $91,000. Finally, Quantamental Technologies LLC acquired a new stake in shares of BridgeBio Pharma in the 1st quarter valued at about $104,000. 96.46% of the stock is currently owned by institutional investors and hedge funds.

About BridgeBio Pharma

(Get Rating)

BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

See Also

Earnings History and Estimates for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.